Search - tctmd.com

Displaying 761 - 780 of 1893

Sort: Relevancy | Date

VITAL: No Benefits to Vitamin D and Omega-3s in Reducing Major CV Events, Cancer

News Conference News AHA 2018

VITAL: No Benefits to Vitamin D and Omega-3s in Reducing Major CV Events, Cancer

November 10, 2018

NIH Presses Pause on Cardiac Stem Cell Trial, Further Muddying a Murky Field

News Daily News

NIH Presses Pause on Cardiac Stem Cell Trial, Further Muddying a Murky Field

November 02, 2018

INR Test Strips Recalled Due to Inaccurate Measurements

News Daily News

INR Test Strips Recalled Due to Inaccurate Measurements

November 02, 2018

Diabetes Drug Canagliflozin Gets MACE Reduction Indication

News Daily News

Diabetes Drug Canagliflozin Gets MACE Reduction Indication

November 01, 2018

Dabigatran Trials Come Up Short for Stroke of Unknown Cause and Cerebral Venous Thrombosis

News Daily News

Dabigatran Trials Come Up Short for Stroke of Unknown Cause and Cerebral Venous Thrombosis

October 26, 2018

Low Temps, Harsh Weather Linked to MI Risk, Swedish Study Confirms

News Daily News

Low Temps, Harsh Weather Linked to MI Risk, Swedish Study Confirms

October 25, 2018

Complete Revascularization Improves Long-term NSTEMI Outcomes, Cohort Study Suggests

News Daily News

Complete Revascularization Improves Long-term NSTEMI Outcomes, Cohort Study Suggests

October 16, 2018

Post-MI Beta-blocker Use Dropped During Metoprolol ER Shortage, but Outcomes Unaffected

News Daily News

Post-MI Beta-blocker Use Dropped During Metoprolol ER Shortage, but Outcomes Unaffected

October 15, 2018

Procedural Success Increasing for CTO PCI in Europe, Despite More Complex Lesions

News Daily News

Procedural Success Increasing for CTO PCI in Europe, Despite More Complex Lesions

Yael L. Maxwell

October 15, 2018

FDA Approves Rivaroxaban for CV Event Reduction in CAD and PAD Patients

News Daily News

FDA Approves Rivaroxaban for CV Event Reduction in CAD and PAD Patients

October 12, 2018

GALILEO Trial of Rivaroxaban After TAVR Stopped Early for Harm

News Daily News

GALILEO Trial of Rivaroxaban After TAVR Stopped Early for Harm

October 09, 2018

DOACs Safe, Effective in A-fib Patients With Preexisting LAA Thrombus

News Daily News

DOACs Safe, Effective in A-fib Patients With Preexisting LAA Thrombus

October 04, 2018

Stay Away From Warfarin-Based Triple Therapy in Patients With A-fib and CAD, Study Affirms

News Daily News

Stay Away From Warfarin-Based Triple Therapy in Patients With A-fib and CAD, Study Affirms

October 03, 2018

NEOPRO: Two Next-Gen TAVR Valves Show Promise at 30 Days

News Conference News TCT 2018

NEOPRO: Two Next-Gen TAVR Valves Show Promise at 30 Days

Yael L. Maxwell

September 25, 2018

TAVR Superior to Surgery at Getting High-Risk Patients Home Sooner

News Daily News

TAVR Superior to Surgery at Getting High-Risk Patients Home Sooner

Michael O'Riordan

September 20, 2018

Out-of-Hospital Cardiac Arrest Protocol With Cooling, Angiography Gets ‘Extraordinary’ Results

News Daily News

Out-of-Hospital Cardiac Arrest Protocol With Cooling, Angiography Gets ‘Extraordinary’ Results

September 19, 2018

Lack of Short-term Cancer Risk With Tainted Valsartan ‘Reassuring’

News Daily News

Lack of Short-term Cancer Risk With Tainted Valsartan ‘Reassuring’

September 13, 2018

Good INR Control on Warfarin Doesn’t Necessarily Predict Future Success, Outcomes

News Daily News

Good INR Control on Warfarin Doesn’t Necessarily Predict Future Success, Outcomes

September 13, 2018

Early Discharge Safe in Patients Undergoing TAVR, Meta-analysis Shows

News Daily News

Early Discharge Safe in Patients Undergoing TAVR, Meta-analysis Shows

Michael O'Riordan

September 12, 2018

TAVR Learning Curve, Volume-Outcome Relationship Highlighted in International Registry

News Daily News

TAVR Learning Curve, Volume-Outcome Relationship Highlighted in International Registry

September 11, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.